Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular changes in basal cell carcinoma undergoing electrochemotherapy or photodynamic therapy
2024-518228-63-01Phase 2Completed
- Sponsor
- Region Zealand
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bleomycin in basal cell carcinoma (BCC) (2 arms), sponsored by Region Zealand. Primary endpoint: Microvascular changes in basal cell carcinoma during non-surgical treatment using D-OCT. Started Nov 2024; status: completed.
02
Drugs
bleomycin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2024-518228-63-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518228-63-01.